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1. Introduction 
In the recent years progress in the basic laboratory science has allowed for implementation of 
many advanced methods in the clinical practice. Thereupon French- American- British Group 
(FAB) classification of acute leukemias and the immunological classification, published in 1995 
by European Group for the Immunological Characterization of Leukemias (Bene, 1995), were 
changed into WHO 2008 classification, which applied genetic investigations to differentiate 
subtypes of acute leukemia (WHO, 2008). In the former classifications, lymphoma and 
leukemia were diagnosed as distinct disorders. Apart from including lymphoma and leukemia 
in the WHO 2008 classification as a single disease, acute lymphoblastic leukemia (ALL) can be 
diagnosed if over 20% (in some investigations over 25%) lymphoblast infiltration is detected in 
bone marrow biopsy. In this new classifications precursor lymphoid neoplasms are divided 
into the B (about 80% of cases) or T cell lineage (about 15-25%). ALL diagnosis, based on 
antigen B or T investigation, uses flow cytometry method. Recent investigations suggest 
different molecular profiles for ALL-T type and T-lymphoblastic lymphoma especially an 
expression of CD47 in T -ALL, and over-expression of MLL1 in T- lymphoblastic lymphoma 
(Hoelzer & Gokbuget, 2009; Raetz et al., 2006). The prevalence of ALL in children amounts to 
30-35% of neoplastic diseases and its incidence is approximately 40 cases in a million per year. 
In adults ALL account for about 20% of all types of acute leukemia. The incidence in adults is 
estimated as 0,39 per 100 000 per year in 35-39 age range, and increases to 2,1 patients over 80 
years (Anino et al., 2002). The distinction of various ALL subtypes characterized by recurrent 
genetic abnormalities was made possible thanks to specific genetic studies. The incidence of 
the diagnosed subtypes occurring in adult and children population varies and indicates 
differences in the clinical features (Harrison, 2008). Cytogenetic studies have become a routine 
procedure in clinical practice involved in acute leukemia treatment (Faderl et al., 1998). 
Carrying out of the above-mentioned methods is an indispensable condition to make a proper 
diagnosis according to WHO 2008 classification. 
Cytogenetic studies implicate specific types of therapy in adults and children as well 
(Tomizawa et al., 2007). 
However, the results of treatment of ALL patients improved not only because of better 
treatment modality standards and facilities but also thanks to proper and detailed diagnosis 
(Faderl et al., 2010).  
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I. 
 
B lymphoblastic 
leukemia/lymphoma  
1. B lymphoblastic leukemia/lymphoma, not otherwise 
specified 
2. B lymphoblastic leukemia/lymphoma with recurrent 
genetic abnormalities 
- B lymphoblastic leukemia/lymphoma with 
t(9;22)(q34;q11.2); BCR-ABL1 
- B lymphoblastic leukemia/lymphoma with t(v;11q23);MLL 
rearranged 
- B lymphoblastic leukemia/lymphoma with 
t(12;21)(p13;q22);TEL-AML1 (ETV6-RUNX1) 
- B lymphoblastic leukemia/lymphoma with hyperdiploidy 
- B lymphoblastic leukemia/lymphoma with hypodiploidy 
(Hypodiploid ALL)  
- B lymphoblastic leukemia/lymphoma with 
t(5;14)(q31;q32);IL3-IGH 
- B lymphoblastic leukemia/lymphoma with 
t(1;19)(q23;p13.3);E2A-PBX1(TCF3-PBX1) 
II. 
T lymphoblastic 
leukemia/lymphoma 
 
Table 1. Precursor Lymphoid Neoplasms Classification WHO 2008. 
2. Flow cytometry 
Flow cytometry is a method, which is most commonly used for clinical diagnosis of ‘de 
novo’ acute leukemias, and as such does not require any additional preparation on the part 
of the patient. It is the method of sorting and measuring types of cells by fluorescent 
labelling of monoclonal antibodies on the surface or in cytoplasm of investigated cells. 
Types of an antigen or other markers present on the cell give further information about the 
immunophenotype of leukemic cells. In the method monoclonal antibodies are used for 
detecting antigens determined in CD classification. Despite that, it is not the method of 
cytogenetic examination; the frequent application of immunophenotyping to peripheral 
blood or bone marrow aspiration cells necessitates the description of the flow cytometry in 
this chapter too.  
Flow cytometry investigation of neoplastic cells is commonly used for diagnosis of central 
nervous infiltration of ALL manifested as leptomeningeal disease. The National 
Comprehensive Cancer Network recommends the routine use of the flow cytometry for the 
diagnosis of the central nervous infiltration involvement in ALL (Brem et al., 2008).  
The process of collecting data from samples is performed using a flow cytometer. The data 
generated by flow cytometers are presented as a 'plot' i.e. histogram. The histogram regions 
can be sequentially separated, based on fluorescence intensity, by creating a series of subset 
extractions, called 'gates'. For diagnostic purposes in hematology specific gating protocols 
exist. The WHO 2008 classification divided leukemias/lymphomas into B or T cell types and 
these types of leukemia can be distinguished both by immunophenotype and by molecular 
genetic studies.  
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The B lymphoblasts as well as the T lymphoblasts can express a panel of characteristic 
antigens (Tab.2).  
 
Basic panel 
for diagnosis 
of acute leukemia
Panel of antigens 
for B derived ALL
Panel of antigens 
for T derived ALL 
Minimal residual disease 
monitoring 
CD 45 
CD10 
CD1a 
CD7 
CD22 
CD65 
CD2 
CD13 
CD14 
CD33 
CD34 
CD117 
CD15 
CD56 
 
Additionally: 
CD16, CD66, 
CD36, CD64, CD 
41, GlyA 
CD11b,CD11c, 
HLADR, CD38,  
CD34 
CD19 
CD10 
CD20 
cyCD22 
CD38 
cyCD79a 
CD9 
CD45 
CD45RA 
IgG2a 
IgG3 
CD52 
CD58 
 
Additionally: 
TdT, sIg, cyIgM, 
cyIgG1, IgG1, IgM,
lambda, kappa 
 
For ALL CD19 
positive: 
CD33, CD13, 
CD117, CD15BD, 
CD2, CD7, CD66, 
CD123 
CD7 
IgG1 
CD2 
CD3 
CD5 
CD4 
CD8 
cy/sCD3 
CD1a 
CD34 
CD38 
CD45 
IgG3 
CD52 
CD99 
 
Additionally: 
cyIgG1, cyCD3 
CD45RA, CD45RO, 
CD25, CD57, CD16 
 
For ALL CD7 
positive: 
CD33, CD13, 
CD117, CD15BD, 
CD56, CD65, CD117
Case nr 1, (B-cell ALL): Qu*: 
CD66c/19 and 
CD10/19/45RA; and 
CD45/19  
or ES**: CD58/19, 
CD10/20/19, CD34/38/TdT, 
CD10/19/TdT, 
CD34/38/TdT, 
CD10/19/TdT 
 
Case nr 2, (B-cell ALL): 
Qu: Cd34/66c/19, 
ES: CD10/19/20, 
CD34/38/19, 
CD45/34/19, 
CD34/9/19, 
CD58/51/19, CD10/19/TdT 
 
Case nr 3, (B-cell ALL): 
CD19/22/34, 
CD19/TdT, 
CD33/HLADr  
  
Case nr 4, (T-cell ALL): 
sCD7/TdT/cCD3, 
CD7+/5+/3 negative, 
CD7+/1a+/3 negative, 
CD4+/8+/3 negative 
Table 2. The list of monoclonal antibodies for diagnosis and monitoring the treatment of 
acute lymphoblastic leukemia  
The progress in the flow cytometry technique allowed to obtain information about 17-60 
parameters of the investigated cells simultaneously (Wood et al., 2006).  
This method, which is useful in diagnosis, can additionally detect a very small number of 
abnormal cells in bone marrow suspension or peripheral blood cells obtained from patients 
after the treatment, hence can detect the minimal (i.e. submicroscopic) residual disease 
(MRD) (Campana, 2009). The panel of antigens for MRD examination is matched 
individually on the basis of the results of immunophenotyping, which is performed during 
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diagnosis. At least two different aberrant phenotypes with the expression over 50% of 
leukemic blasts are used on the average. The following are necessary and useful criteria in 
monitoring MRD: coexpression of antigens from different than lymphoblastic cell lines, e.g. 
CD13, CD33, asynchronous antigens expression or overexpression within the same line and 
ectopic phenotypes. MRD can be evaluated using either the ‘quadrant’ method or ‘empty 
spaces’ technique. Usually, MRD is calculated as the percentage of total nuclear bone 
marrow cells and in 3-8 colour flow cytometry method, where the 0,1% -0,01% sensitivity is 
obtained. Flow cytometry is described as a widely applicable, rapid and accurate 
quantification method which provides additional information on normal hematopoietic cells 
and can differentiate these cells from neoplastic compartment (Figure 1). The potential 
weakness is phenotypic shifts and as a result there are multiple aberrant phenotypes 
required.  
The results of immunophenotyping can be useful in clinical application for identifying 
antigens in targeted therapy, and as a minimal residual disease monitoring during treatment 
(Giebel et al., 2010; Rhein et al., 2010). Targeted therapy involves the use of monoclonal 
antibodies as follows: anti CD20 (rituximab), anti CD52 (alemtuzumab), anti CD22 
(epratuzumab), anti CD 33 (+toxin) (gemtuzumab ozogamycin), and Blinatumomab used 
recently (Nijmeijer et al., 2010; Raetz et al., 2008; Topp et al., 2009; Topp et al., 2011). 
 
Bone marrow samples were stained using MoAb: CD34-FITC / CD38-PE / CD19-PC5 
Diagram ‘dot plot’ showed only CD19(+) cells  
Normal B-Lymphocytes – shaded area  
Lymphoblasts – dash area  
Fig. 1. Empty Spaces method for MRD monitoring during ALL CD19+ treatment. The figure 
shows the bone marrow samples examination. 
ALL - Blasts infiltration in diagnosis 
ALL - MRD after first 
induction treatment 
ALL - REMISSION
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3. Cytogenetic methods used in acute lymphoblastic leukemia 
Cytogenetic changes underline leukemogenesis targeted and are closely associated with the 
type neoplasm developing. Several cases of precursor lymphoid neoplasms have 
characteristic genetic abnormalities that are important in determining their biologic and 
clinical features (Harrison, 2001; Mullingan, 2009). Some of mutations occurred both in ALL 
and in AML, e.g. FLT3 mutations (point mutations and internal tandem duplications (Chang 
P., 2010). Chromosomal abnormalities are detected in about 80% of ALL cases but in about 
40% numerical abnormalities exist and in 40% there are structural alterations (Witt et al., 
2009). Over the years, methods of cytogenetic analysis evolved and became a part of routine 
laboratory testing, providing valuable diagnostic and prognostic information in children 
and adult patients (Park et al., 2008). The reference material for cytogenetic investigation the 
cells obtained during bone marrow aspiration. Peripheral blood cells are used only if bone 
marrow cells are unavailable or if special methods of cytogenetic investigation are used e.g. 
fluorescence in situ hybridization or polymerase chain reaction instead of conventional 
cytogenetics.  
3.1 Conventional cytogenetics and fluorescence in situ hybridization 
The gold standard for cytogenetical investigation is still conventional cytogenetics (Figure 2) 
but now often combined with analyses using fluorescence in situ hybridization (FISH), and 
polymerase chain reaction (PCR) technique.  
 
Fig. 2. Results of conventional cytogenetic investigation in ALL patients (GTG method). 
Images show the t(4;11) and t(9;22). 
For cytogenetical investigation the sample of 2-3ml volume from bone marrow aspiration or 
5-10ml from peripheral blood, with the addition of heparin, must be delivered to cytogenetic 
laboratory in 24 hours, and can be transported in a room temperature. This diagnostic 
procedure must be carried out before the start of any antineoplastic treatment. The main 
elements of the cytogenetical methods are cell cultures which are mandatory for obtaining 
metaphases for chromosomal analysis. The duration time of cells cultures oscillates from 
0,4-2 hours (called ‘immediate’) to 24, 48 and 96 hours. Then cytogenetical analysis of cells is 
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performed in metaphases and the rest of cell suspension can be left in minus 20 Celsius 
degree for additional investigations. According to the guidelines of European 
Cytogeneticists Association (ECA), prepared as a quality framework for cytogenetic 
laboratories, diagnostic metaphases must be obtained from at least 90% of cell cultures 
(Bricarelli et al., 2006). The minimum number of metaphases required to obtain the result, is 
20 in normal karyotype. If the karyotype is abnormal the number of metaphases may be 
lower (sometimes only few metaphases) providing that clonal aberrations are recurring 
(Haferlach et al., 2007). Cytogenetic findings were reported up to 3 weeks after the sample 
had been received in laboratory. There are some limitations of conventional cytogenetic 
analysis such as sometimes morphologically insufficient quality of metaphases or the 
mitotic index. The paper presents results of investigation of 70 ALL in children revealed, 
that karyotypes were obtained in 84% (Soszynska et al., 2008).  
Fluorescence in situ hybridization method (FISH) is a cytogenetic technique providing 
detection of characteristic chromosomal DNA sequences, by painting them. FISH is a 
method of supplementing the classical cytogenetic studies, but can also be an independent 
method for cytogenetic analysis in ALL. Principle of FISH is the use of DNA fragments 
precisely defined sequence, that is, molecular probes of complementary hybridizing 
appropriately prepared DNA test. Special locus-specific probe mixtures are used to count 
chromosomes. Fluorescence microscopy can be used to find out where the fluorescent sound 
is bound to the chromosome. To determine the percentage of cells with genetic 
abnoramalities sought is indicated in the analysis of at least 100 interphase or metaphase 
cells. There are some modifications of FISH technique that were implemented in hematology 
laboratories e.g. multiple colour FISH (M-FISH) is widely applied for detection of BCR/ABL 
translocation and for MLL gene rearrangements. Employed ratios of probe mixtures are 
supposed to create secondary colours that are useful in differentiating subtypes of ALL. 
M-FISH elucidated complex karyotypes (Broadfield et al., 2004; Harrison et al., 1999). 
Results of FISH and conventional cytogenetics should be determined in accordance with the 
International System for Human Cytogenetic Nomenclature (ISCN, 2005).  
In ALL diagnostic procedures FISH testing should always be done if: 
1. In the conventional cytogenetic study, no metaphases were obtained or the quality is 
not suitable for release as a result, 
2. The outcome of conventional cytogenetics GTG technique suggests the presence of 
aberrations, but does not confirm it, 
3. In conventional cytogenetics was not found chromosome aberrations characteristic for 
the type of leukemia (e.g. the CD10 positive leukemia with Ph cryptic or masked Ph).  
The new technique, which detected chromosomal imbalances, introduced by Kallioniemi 
(Kallioniemi1 et al., 1994) is comparative genomic hybridization (CGH), which is a method 
of molecular cytogenetics. CGH gives a global overview of chromosomal deletions and 
amplifications throughout the whole genome with one step analysis (McGrattan et al., 2008). 
CGH can detect submicroscopic deletions 5-10Mbp in size and detect extra-chromosomal 
fragments of chromatin size 2-3Mpz. The major limitation of CGH, however, is the failure to 
detect balanced chromosome abnormalities such as translocations, inversions, and clonal 
heterogeneity (Ness et al., 2002). This method can be performed as a complementary test 
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GTG and FISH. CGH could be established as a routine method of analysis for screening 
patients with ALL (Kowalczyk et al., 2010).  
Test result conventional cytogenetics and FISH help determine the specific subtype of ALL 
diagnosis, identify risk factors, establishing prognosis, treatment selection, is also to monitor 
the disease and the effectiveness of treatment. 
 
Fig. 3. Results of FISH method detecting translocations in All patients: t(9;22) and t(4;11). 
3.2 Polymerase chain reaction 
The polymerase chain reaction (PCR), a technique of molecular biology now is a routinely 
used method for ALL diagnosis as well as for categorizing ALL subtypes according to 
WHO2008 classification, monitoring the treatment results and measurement of minimal 
residual disease too.  
For PCR investigation the sample of 1-5ml volume from bone marrow aspiration or 5-10ml 
from peripheral blood, with the addition of EDTA, must be delivered to cytogenetic 
laboratory in 24 hours, and must be transported in +4oC.  
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PCR has a very high sensitivity and detects known fusion events (Wesołowska et al., 2011). 
Suitably selected set of primers can detect aberrations at the RNA level (the method of RT-
PCR). There are some variants of PCR technique which are very useful in hematological 
investigation e.g. single-nucleotide polymorphisms (SNPs), Asymmetric PCR, Multiplex-
PCR, Nested PCR, Quantitative PCR (Q-PCR), Quantitative real-time PCR, Reverse 
Transcription PCR (RT-PCR). The RT-RQ-PCR method can detect translocation-specific 
malignant lymphoblasts at a sensitivity determined as 10 -4 - 10-6. The method is used for 
monitoring MRD and its advantage is the stability of gene fusion in the course of the 
disease, and high sensitivity determinations. The disadvantage of RT-RQ-PCR is the lability 
of RNA and the possibility of its application only in a small group of patients because of the 
limited frequency of gene fusions in ALL.  
In the monitoring of MRD may be used the following gene fusions: BCR-ABL1, MLL-AFF1, 
TCF3-PBX1 and ETV6-RUNX1, present in approximately 40% of pediatric and adults 
patients (Campana, 2009; Bruggemann et al., 2010), and IGH@-CRLF2 or P2RY8-CRLF2 
abnormalities, which are detected in about 15% of adult or high risk pediatric B-ALL (Yoda 
et al., 2010).  
The most common method of MRD detection is based on the sequence of rearranged Ig gene 
joints/TCR, encoding the immunoglobulin and T cell receptors in response real-time 
quantitative polymerase chain reaction. The method can be used in more than 95% of ALL 
patients and has a sensitivity of 10 -4 to 10 -5. The Ig/TCR RQ-OCR method is complicated, 
time-consuming and cost-intensive, but nevertheless is regarded in Europe as the 'gold 
standard' in the monitoring of MRD. This is due to the large stage of standardization, 
comprising the steps research, primers and probes, as well as guidelines on the 
interpretation of the data obtained his allows receive high reproducibility of results in the 
determination of risk groups and assessment of MRD that is necessary in conducting 
multicenter studies (Witt et al., 2009). 
3.3 Microarray analysis of genetic abnormalities in ALL 
Microarray platforms for analysis of genetic alterations include cDNA array (detected large 
alterations, often over 100kB) and oligonucleotide arrays (oligo array, used short 20-50kB 
nucleotide probes). The potential of high-density microarray of specific cDNA sequences 
allows for hybridization of fluorescently labelled mRNA of leukemic cells. The value of this 
technique for the diagnosis and follow-up of ALL specific genetic abnormalities is 
enormous. Protein microarrays were used to investigate Notch-transduced signals in the 
development of T-cell ALL (Chan et al., 2007). The identification of novel miR genes 
expressed in different types of ALL forms the basis for further studies of the biology of ALL 
(Schotte et al., 2011). 
4. Genetic differences and similarities amongst B and T derived ALL 
4.1 B-cell acute lymphoblastic leukemia (B-ALL) 
During the B-cell ontogenesis the V,D and J segments are rearranged to generate a unique 
gene sequence for each cell. The distinctive genetic abnormalities occurring in B-derived 
ALL are as follows: clonal DJ rearrangements of IGH@gene, T-cell receptor rearrangements 
noticed in 70% of B-ALL, which are not helpful in differentiating from T-cell ALL, t(9;22) 
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mainly found in adults patients, t(12;21) and hyperdiploidy (usually without structural 
abnormalities) occurring mainly in children. In B-type of ALL del(6q), del(9p), del(12p), 
t(17;19) and intrachrmomosomal amplification of chromosome 21 (iAMP21) are often 
detected. 
The t(12;21) occurs most frequently in children, and probably arose early in pregnancy. This 
genetic abnormality causes the fusion of two genes AML1 and TAL, resulting disorder in an 
early stage of B cell development.  
Adults most often found in t(9;22), which causes the fusion of BCR and ABL genes and leads 
to the fusion protein BCR-ABL1 (tyrosine-kinase) that interacts with multiple signal paths 
(eg RAS).  
 
Translocation Gen Function Prevalence % 
adults/children 
Detection for 
MRD 
monitoring 
t(9;22)(q34;q11) BCR-ABL Enhanced tyrosine 
kinase activity, 
which function in 
intracellular 
signalling pathways
<25>/5-8 mRNA 
t(4;11)(q21;q23) MLL-AF4 Transcription factor 
in the regulation of 
differentiation 
pathways  
6/2-7 mainly in 
infants 
mRNA 
t(1;19)(q23;p13) E2A-PBX Transcription factor  /<6 (25-30% in 
pre-B-ALL) 
mRNA 
t(12;21)(p13;q22) TEL-AML1 Transcription factor <2/1-2 mRNA 
11q23 aberrations MLL and any 
one of fusion 
partners 
Transcription factor 3-4/5-6 mRNA 
Table 3. Structural chromosome abnormalities in B type of ALL 
4.2 T-cell acute lymphoblastic leukemia (T-ALL) 
Clonal rearrangements of T-cell receptor (TCR) genes, an abnormal karyotype, translocations 
and chromosomal deletions almost always occurred in T-derived ALL (Table 4). About 20 % 
of patients diagnosed as T-ALL displayed immunoglobulin gene rearrangements as well 
(Szczepański et al., 1999). The abnormal karyotype is present in about 50-70% of cases and 
mainly involves the alpha and delta TCR(14q11.2), the beta locus (7q35) and the gamma 
locus (7p14-15).  
Translocations 
These genetic abnormalities are surrounded by translocations of the partner gene. The most 
frequently involved genes are as follows: HOX11 (TLX1) (10q24) occurred in 30% of adults 
and in 7% of pediatric patients, HOX11L2 (TLX3) (5q35) found in 10-15% of adults and in 
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20% of children. There are transcription factors. The other transcription factors engaged in 
translocations are MYC (8q24.1), TAL1 (p32), RBTN1 (LMO1) (11p15), RBTN2 (LMO2) 
(11p13), LyL1 (19p13) and the cytoplasmic tyrosine kinase LCK (1p34.3-35). In about 10-8% 
of patients other translocations occurred as follows: PICALM-MLLT10 [CALM-AF10; 
t(10;11)(p13q14)] and MLL most often with the partner gene ENL (19p13). The translocations 
are often not detected by conventional cytogenetic methods hence PCR must be used 
(WHO, 2008).  
Deletions 
Del(9p) is the most frequently occurring deletion (in about 9% of cases), detected mainly by 
PCR method, only 30% can be detected by conventional cytogenetics (Brett-Gardiner et al., 
2011). 
Gene mutations 
In over 50% of T-ALL cases NOTCH1 gene mutations were found. The NOTCH1 signalling 
pathway has three components and the mature NOTCH1 protein which is essential for early 
T-cell development (Liu et al. 2011; Palomero & Ferrando A., 2009).  
Brain and Acute Leukemia, Cytoplasmic (BAALC) gene expression 
BALLC gene is located on chromosome 8q22.3. Its high expression (overexpression) in the T-
cell ALL is associated with worse overall survival and relapse-free survival. Kuhn et al. 
demonstrated, that high BAALC expression is associated with inferior overall survival also 
in adults B-precursor ALL patients. BAALC overexpression can be regarded as an additional 
negative prognostic factor in adult ALL patients (Kuhnl et al., 2010).  
5. Treatment of acute lymphoblastic leukemia patients 
The main treatment rule for patients with acute lymphoblastic leukemia is to adjust the 
intensity of treatment to the level of disease aggression. This fact accounts for a wide 
application of protocols for risk-adapted therapy in everyday clinical practice. Clinical and 
biologic features which were defined as risk factors formerly (Table 5) are now replaced by 
minimal residual disease estimation (Attarbaschi et al., 2008; Bassan et al., 2009; Conter et 
al., 2010). 
There are the same treatment protocols for B and T derived ‘de novo’ acute lymphoblastic 
leukemia. However, during the relapse of T-ALL other medications are recommended such 
as: Nelarabine, Forodesine and Clofarabine (De Angelo, 2009 ). Most European Groups use 
regimens containing prednisolone/dexamethasone, vincristine, daunorubicin and 
asparaginase in the induction phase of treatment of adult All patients (Conter et al., 2010; 
Bassan et al., 2009; Patel et al., 2010). 
During consolidations additional chemotherapy using cyclophosphamide, cytarabine is 
administered, and including intensive intrathecal chemotherapy. Maintenance 
chemotherapy lasting 2-3 years consists of low-dose antineoplastic drugs, mainly of 
mercaptopurine and methotrexate (Holowiecki et al., 2006).  
Hyper CVAD (cyclophosphamide, vincristine, adramycin and dexamethasone, without L-
asparaginase) is a reasonable alternative for induction therapy and gives results similar to  
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Translocation Gen Function Prevalence % 
adults/children
Detection for 
MRD 
monitoring 
t(1;14)(p32;q11)  TAL1(SCL) Transcription 
factor 
/3 DNA (TAL1-
TCRD) 
t(11;14)(p15;q11) RBTN1(i1) Transcription 
factor  
 
/9 DNA  
(LMO1-TCRD) 
t(11;14)(p13;q11) RBTN2(LMO2) Transcription 
factor 
 /4-5  DNA 
(LMO2-TCRD) 
t(10;14)(q24;q11) 
t(7;10)(q35;q24) 
HOX11 
HOX11 
Transcription 
factor 
/10 DNA (HOX11-
TCRD or TCRB) 
inv(7)(p15q34) HOXA Transcription 
factor  
/5 mRNA 
(HOXA-TCRB) 
t(5;14)(q35;q32) HOX11 Transcription 
factor 
10-15/20 mRNA 
(HOX11L2-
BCL11B) 
t(1;14)(p34;q11) LCK Transcription 
factor 
3/3 DNA 
(TAL1-TCRD) 
t(11;19)(q23;p13) MLL-ENL  Transcription 
factor 
/5 mRNA 
t(7;9)(q34;q32) 
 t(7;9)(q34;q34) 
TAL2  
NOTCH1 
Transcription 
factor 
 
~30/~50 
mRNA 
Del(9)(p21) CDKN2A,CDKN2B Loss of control 
cell cycle 
/65-80 DNA/mRNA 
del(1)(p32) SIL-TAL1 Transcription 
factor 
/10-25 DNA/mRNA 
(SIL-TAL1) 
t(10;11)(p13-
14;q14-21) 
CALM Transcription 
factor 
10/8 mRNA  
(CALM-AF10) 
MLL  MLL-ENL/AF10 etc Transcription 
factor 
8/5 mRNA (MLL-
ENL/AF10 and 
other) 
9p34 episomal 
amplification 
NUP214-ABL Enhanced 
tyrosine kinase 
activity, which 
function in 
intracellular 
signalling 
/6 mRNA 
inv(7)(p15q34) HOXA Transcription 
factor 
 mRNA 
Table 4. Structural chromosome abnormalities in T type of ALL 
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 High risk factors (Hoelzer et 
al., 1988) 
High risk factors PALG 
(Holowiecki et al., 2006) 
Age  >35 years ≥ 35 years 
WBC count >30x10e9/l for B-type ALL 
>100x10e9 for T-type ALL 
≥ 30x10e9/l for B-type ALL 
≥ 100x10e9/l for T-type ALL 
 
Immunophenotype  Prepre-B, early T, mature T Prepre-B, early T, mature T 
Genetics   t(4;11) or t(9;22)  
Time to remission CR after >4 weeks MRD positivity post 
induction or during or post 
consolidation treatment 
Table 5. Clinical and immunological prognostic factors for newly diagnosed adult ALL 
patients 
the traditional induction protocols (Kantarijan et al., 2004). Various protocols for induction 
and consolidation as well as post remission treatment refer to pediatric patients and adults. 
In adult group of patients aged below 30 years some collaborative groups preferred more 
intensive treatment compatibility to pediatric protocols. This more intensive treatment gives 
better results defined as better complete remission rate (e.g. 83 vs 94% in the study of LALA-
94 (adult) and FRALLE-93 (pediatric), respectively), disease free survival (e.g. 5 year EFS 
amounting 38% for adult (HOVON) and 71% for DCOG (pediatric) study, respectively), or 
overall survival (e.g. 5 year OS amounting respectively 56% (UKALLXII/E2993, adult) and 
71% (ALL97, pediatric) (DeAngelo et al., 2007; Barry E. et al., 2007; Boissel et al., 2003; De 
Bont et al., 2005; Ramanujachar et al., 2007; Rijneveld et al., 2009; Testi et al., 2004). 
For more advanced aged patients reduced intensity chemotherapy protocols are used 
generally due to lower tolerance to very intensive therapy (Giebel et al., 2010; Marks, 2010). 
In this age group significantly more frequently occurs high risk factors such as complex 
cytogenetic abnormalities, low hypodiploidy, t(4;11) and t(9;22). Philadelphia chromosome 
positivity (t(9;22)) is a very high risk factor but also allows the conduct of targeted therapy 
with the use tyrosine kinase inhibitors. In these cases, the cytogenetics methods allow the 
use of targeted therapy (Foa et al., 2011).  
ALL occurs in children about five times more frequently than in adults. In recent years 
significantly increased the effectiveness of ALL treatment in the pediatric group of patients 
(Freyer et al., 2011). Surveillance, Epidemiology and End Results register (SEER) analysis 
showed the biggest improvement in survival of patients aged 15-19 years because the 5-year 
overall survival increased from 41 to 62%. Long term survival in between the ages 2 and 10 
years are found in more than 90% (Stock, 2010). These good results of treatment may be due 
inter alia to the fact that children are usually treated within the prospective multicenter 
clinical trials, which included the optimal diagnostic methods and used most effective 
treatment. 
Although many genetic abnormalities are important as prognostic factors, only a few have 
an influence on the choice of treatment (Tomizawa et al., 2007). There are some rules 
allowing for the introduction of certain particulars from diagnosis to modifications of  
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High risk factor  
WBC count ≥20G/l 
Age Infants or children ≥10 years 
7-day response to steroid pretreatment Presence of >1 x 109/l blasts in peripheral 
blood  
Ploidy < 45 chromosomes 
Translocations: t(9;22)/BCR/ABL 
t(4;11)/MLL/AF4 
MRD after induction treatment ≥10 -3 
CR after induction of treatment at the 
expected time (33 day of treatment) 
No  
Table 6. Adverse prognostic factors in acute lymphoblastic leukemia in children, which are 
most commonly used in everyday clinical practice.  
patients' treatment and the results of cytogenetic findings are found to be useful. The first 
paper claiming cytogenetic abnormalities to have given important prognostic information 
was published by Secker-Walker (Secker-Walker et al., 1978). The impact of cytogenetics on 
the treatment results was published by Southwest Oncology Group 9400 study (Pullarkat et 
al., 2008). The authors presented the four different karyotype categories (Table 7) in which 
the most important prognostic factor for overall survival and relapse-free survival is 
cytogenetics instead of age.  
 
Risk group Cytogenetics markers 
I. Standard risk  
(5 years overall survival ≥50%) 
Hyperdiploid (>50 and < 66 chromosomes)  
II. Intermediate risk  
(5 years overall survival 40-50%) 
Normal diploid,  
11q23 deletions without MLL 
rearrangements 
del9(p), del6(q), del(17p), del(12p), 
13/del(13q), t(14q32),t(10;14) 
low hypodiploidy (47-50 chromosomes) 
TCR translocations 
Tetraploidy (>80 chromosomes) 
III. High risk  
(5 years overall survival 30-40%) 
t(1;19), 7(Ph-), del(7p), +8,  
11q23/MLL gene and any one of fusion 
partners 
t(17;19), t(5;14)/TLX3, CALM-AF10 
IV. Very high risk  
(5 years overall survival ≤30%) 
t(9;22) BCR-ABL, t(4;11) AF4-MLL,  
t(8;14) MYC-IGH 
Complex (≥5 abnormalities without known 
translocations) 
Low hypodiloidy (30-39) 
Triploidy (60-78) 
Table 7. Risk groups defined using karyotype and genetic categories based on SWOG 
analysis (Pullarkat et al., 2008) 
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Philadelphia chromosome positivity, low hypodiploidy (near triploidy) and complex 
cytogenetic abnormalities (more than five chromosomal changes) influenced shorter overall 
survival (Marks et al., 2009). Sometimes more intensive treatment e.g. modified Hyper-
CVAD regimen gives better results in very high risk ALL with t(4;11) (Li et.al., 2009).  
The translocation between chromosome 9 and 22 results in the formation of the Philadelphia 
chromosome (Ph) and generates the expression of a p 190 protein or encoding a chimaeric 
p210 protein. Ph positivity is more often present in adult patients and the incidence 
increases with the age from 20% in 30 years to 39% in over 60 years (Moorman A.V., 2010). 
In these cases, targeted therapy using tyrosine kinase inhibitors such as imatinib or 
dasatinib is combined with chemotherapy both in young and elderly patients (Foa et al., 
2011; Ravandi et al., 2010; Laport et al., 2008; Ottmann et al., 2007; Tanguy-Schmidt et al., 
2009). These types of combined therapy give better results mostly if allogeneic bone marrow 
transplantation was performed in the first complete remission (Yanada et al., 2008). In 
patients aged above 60 years chemotherapy should be reduced, and limited to administer 
monotherapy, imatinib 600-800mg/day, or in combination with glucocorticoids and/or 
vincristin (Ottmann, Wassmann et al., 2007). 
5.1 Minimal residual disease testing 
Many publications have shown that the MRD positivity has prognostic value for the 
treatment results of children and adults ( Moricke et al., 2008; Stow et al., 2010; Hoelzer et 
al., 1988; Holowiecki et al., 2008). Result of the MRD examination is important in monitoring 
the induction and consolidation treatment (Figure 4), and in terms of eligibility for bone 
marrow transplantation (Couston-Smith et al., 2011; Giebel et al., 2010). MRD testing can be 
performed using the flow cytometry method or PCR and/or FISH. 
In our paper published by Giebel et al. (Giebel et al., 2009) we documented that MRD 
measured by flow cytometry combined with cytogenetics replaces conventional risk criteria 
in adults with Ph-negative acute lymphoblastic leukaemia as the relapse rate is significantly 
lower in standard risk karyotype or intermediate risk karyotype and MRD lower than 0,1% 
after induction treatment according to the PALG 4-2002 protocol (Figure 5).  
6. Allogeneic transplantation in ALL patients 
Provide for the implementation of EBMT recommendations, bone marrow transplantation 
(the family donor and from an unrelated donor, and autotransplantation) during the second 
remission. For the decision on the application of allogeneic bone marrow transplantation 
(BMT) is to monitor MRD. Many research groups recommends allogeneic BMT in first 
remission period already, in patients at a high risk of leukemia, which is defined of t(9;22), 
t(4;11) occurrence and also hipodiploid (near haploid) karyotype (Ferra et al., 2010; Marks et 
al., 2008; Marks et al., 2010).  
The presence of MRD after induction and/or consolidation treatment is also classified as 
high risk and is an indication for early performing allogeneic bone marrow transplantation. 
The sensitivity of MRD at a level of 10-5 can justify reducing the strength of the treatment in 
some specific cases. Patients of the latter group needs to step up therapy and eligibility for 
allogeneic bone marrow transplantation. 
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Fig. 4. The influence MRD test result on the effectiveness of treatment of adult ALL patients 
according to the protocol PALG 4-2002 (Holowiecki et al., 2008). 
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Fig. 5. Relapse incidence for Ph-negative ALL according to stratification criteria based on the 
combination of karyotype and minimal residual disease status. Karyotype risk groups were 
defined as proposed by Moorman et al (2007) SR indicates standard risk i.e. the presence of 
either del(9p) or high hyperdiploidy; HR, high risk i.e. the presence of t(4;11), t(8;14), 
hypodiploidy/almost triploidy or complex karyotype; IR, intermediate risk i.e. all 
remaining patients (Giebel et al., 2009). 
7. Conclusions 
The introduction of the WHO 2008 classification forces implementation of cytogenetic 
methods into the diagnostic procedures. Conventional cytogenetic and genetic aberrations 
analysis must be conducted in each case of acute lymphoblastic leukemia. Some genetic 
abnormalities cause the application of targeted therapy, the main example is the use of 
tyrosine kinase inhibitors in cases of the t(9;22). Cytogenetic methods, evaluating the 
minimal residual disease, are useful for optimization of the treatment strategy especially for 
recommendation of the allogeneic hematopoietic stem cell transplantation which is 
performed in high risk patients during the first complete remission. 
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